HemoGenyx Pharmaceuticals Plc (GB:HEMO) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Hemogenyx Pharmaceuticals is set to launch its Phase I clinical trial for HEMO-CAR-T, a promising new therapy targeting relapsed/refractory acute myeloid leukemia in adults, marking a significant milestone for the company. The trial, designed to assess safety and efficacy, will commence following anticipated approval and site initiation in November. This development reflects Hemogenyx’s commitment to offering innovative solutions for patients with limited treatment options.
For further insights into GB:HEMO stock, check out TipRanks’ Stock Analysis page.
